The global governance of communicable diseases: The case for vaccine R&D

Law and Policy

Volumn 27, Issue 1, 2005, Pages 33-51

  Archibugi, Daniele ^a,b   Bizzarri, Kim ^a  

^a CNR   (Italy)

^b HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 27844438138     PISSN: 02658240     EISSN: 14679930     Source Type: Journal    
DOI: 10.1111/j.1467-9930.2004.00190.x     Document Type: Article

References (59)

1. Arrow, Kenneth (1962) "Economic Welfare and the Allocation of Resources For Invention." In The Rate and Direction of Inventive Activity, edited by R. Nelson. National Bureau of Economic Research. Princeton, N.J.: Princeton Univ. Press.
2. Aylward, Bruce (2000) "When is a Disease Eradicable? 100 Years of Lessons Learned," American Journal of Public Health 90: 1515-20.
3. Barnett, Tony, and Alan Whiteside (2002) AIDS in the 21st Century: Disease and Globalisation. New York: Palgrave MacMillan.
4. Bell, Clive, Shantayanan Devarajan, and Hans Gersbach (2003) The Long-run Economic Costs of AIDS: Theory and Application to South Africa. Washington, D.C.: World Bank.
5. Buse, Kent, and Gill Walt (2000) "The United Nations and Global Public-Private Health Partnerships." Paper presented at the Workshop: Public-Private Partnerships in Public Health, Harvard School Of Public Health, Boston, 7-8 April.
6. Correa, Carlos (2003) Managing the Provision of Knowledge: The Design of Intellectual Property Laws. In Providing Global Public Goods: Managing Globalisation, edited by I. Kaul, P. Conceição, K. Le Goulven & R. Mendoza. New York: Oxford Univ. Press.
7. Cunningham, Anne Marie (2003) "The Global Fund - All You Ever Wanted To Know." Available at http://www.geocities.com/jvidalalaball/ TheglobalFund.doc.
8. Coriat, Benjamin, and Fabienne Orsi (2002) "Establishing a New Intellectual Property Rights Regime in the United States: Origins, Content and Problems," Research Policy 31: 1491-1507.
9. Desai, Meghnad (2003) Public Goods: A Historical Perspective. In Providing Global Public Goods: Managing Globalisation, edited by I. Kaul, P. Conceição, K. Le Goulven & R. Mendoza. New York: Oxford Univ. Press.
10. DiMasi, Joseph (1991) "Cost Of Innovation In The Pharmaceutical Industry," Journal of Health Economics 10(2): 107-42.
11. Esparza, Jose (2000) "Is an AIDS Vaccine Possible?," UN Chronicle 37(3): 22-23.
12. European Council (2002) Presidency Conclusions. Barcelona European Council. Brussels: EC.
13. Fenner, Frank (1988) Smallpox and Its Eradication. Geneva: WHO.
14. Fidler, David (2001) International Law and Global Communicable Disease Control. Geneva: WHO Commission on Macroeconomics and Health.
15. Frank, Richard (2003) "New Estimates of Drug Development Costs," Journal of Health Economics 22: 325-30.
16. Glasius, Marlies, Mary Kaldor, and Helmut Anheier (eds.) (2001) Global Civil Society Yearbook. Oxford: Oxford Univ. Press.
17. Glasius, Marlies, Mary Kaldor, and Helmut Anheier (Eds) (2002) Global Civil Society Yearbook. Oxford: Oxford Univ. Press.
18. Glasius, Marlies, Mary Kaldor, and Helmut Anheier (Eds) (2003) Global Civil Society Yearbook. Oxford: Oxford Univ. Press.
19. Grabowski, Henry George, and James Vernon (1994) "Returns to R&D on New Drugs Introductions in the 1980s," Journal of Health Economics 13: 383-406.
20. Harvard Malaria Initiative (2000) "The Ancient Scourge of Malaria." Available at http://www.hsph.harvard.edu/Malaria.
21. Heller, Michael, and Rebecca Eisenberg (1998) "Can Patents Deter Innovation? The Anticommons in Biomedical Research," Science 280: 698-701.
22. International AIDS Vaccine Initiative (2001) A New Access Paradigm: Public Sector Actions to Assure Swift, Global Access to AIDS Vaccine. New York: IAVI.
23. International AIDS Vaccine Initiative (2002) When Will an AIDS Vaccine be Found? The State of Global Research. New York: IAVI.
24. Kaufmann, Stephan. (2000) "Is the Development of a New Tuberculosis Vaccine Possible?," Nature America 6: 955-59.
25. Kaul, Inge, Pedro Conceição, Katell Le Goulven, and Ronald Mendoza (eds.) (2003) Providing Global Public Goods: Managing Globalisation. New York: Oxford Univ. Press.
26. Kaul, Inge, and Michael Faust (2001) "Global public goods and health: taking the agenda forward," Bulletin of the World Health Organization 79: 869-74.
27. Kremer, Michael (2001) Public Policies to Stimulate Development of Vaccines and Drugs for Neglected Diseases. Working Paper No. WG2. Geneva: Commission on Macroeconomics and Health.
28. Love, James (2003) "From TRIPS to RIPS: A Better Trade Framework to Support Innovation in Medical Technologies." Workshop on Economic issues related to access to HIV/AIDS care in developing countries held on 27 May 2003. Marseille: Agence nationale de recherches sur le sida/Institute d' économie publique.
29. Love, James, and Tim Hubbard (2004) "A New Trade Framework for Global Healthcare R&D," PLoS Biology 2(2): 147-50.
30. Lundvall, Bengt Ake, and Björn Johnson, (1994) "The Learning Economy," Journal of Industry Studies 1(2): 23-42.
31. Mansfield, Edwin, Mark Schwartz, and Samuel Wagner (1981) "Imitation Costs and Patents: An Empirical Study", Economic Journal 91: 907-918.
32. Mazzoleni, Robert, and Nelson, Richard (1998) "The Benefits and Costs of Strong Patent Protection: A Contribution to the Current Debate," Research Policy 27: 273-84.
33. May, Christopher (2002) "Unacceptable Costs: The Consequences of Making Knowledge Property in a Global Society," Global Society 16(2): 123-44.
34. Médicins Sans Frontières (2001a) Fatal Imbalance: The Crisis in Research and Development for Drugs for Neglected Diseases. Geneva: MSF.
35. Médicins Sans Frontières (2001b) A Survey of Private Sector Drug Research and Development. Switzerland: the Drugs for Neglected Diseases Working Group.
36. Miller, Henry (1998) "Rising Costs hold up Drug Discovery," Nature: 395: 835.
37. Nelson, Richard (1962) The Rate and Direction of Inventive Activity: National Bureau of Economic Research. Princeton, N.J.: Princeton Univ. Press.
38. Pavitt, Keath (1999) "On the Nature of Technology." In Technology, Management, and Systems of Innovation, edited by K. Pavitt. Cheltenham, UK: Edward Elgar.
39. Pogge, Thomas (2002) World Poverty and Human Rights. Cambridge: Polity Press.
40. Poku, Nana (2002) "Global Pandemics: AIDS." In Governing the Global Polity, edited by D. Held & A. McGrew. Cambridge: Polity Press.
41. Polanyi, Michael (1962) Personal Knowledge. Towards a Post-Critical Philosophy. London: Routledge & Kegan Paul.
42. Rabinovich, Regina (1994) "Vaccine Technologies: View to the Future," Science 265: 1401-4.
43. Seckinelgin, Hakan (2002) "Time to Stop and Think: HIV/AIDS, Global Civil Society, and People's Politics." In Global Civil Society, edited by M. Glasius, M. Kaldor & H. Anheier. Oxford: Oxford Univ. Press.
44. Shiva, Vandana (2001) Protect or Plunder?: Understanding Intellectual Property Rights. London: Zed Books.
45. Stiglitz, Joseph (1999) ́Knowledge as a Global Public Good.́ In Global Public Goods: International Cooperation in the 21st Century, edited by I. Kaul et al. New York: Oxford Univ. Press.
46. Tan, Darrel (2003) ́Global Plagues And The Global Fund: Challenges,́ BMC International Health and Human Rights 3(2): 1-9.
47. TB Alliance (2001) The Economics of TB Drug Development. New York: TB Alliance.
48. Tenkorang Dyna Arhin, and Pedro Conceiçao (2003) "Beyond Communicable Disease Control: Health in the Age of Globalisation." In Providing Global Public Goods: Managing Globalisation, edited by I. Kaul et al. New York: Oxford Univ. Press.
49. Thurow, Lester (1997) ̧Needed: A New System of Intellectual Property Rights," Harvard Business Review (Fall): 95-103.
50. Tufts Center for the Study Of Drug Development (2003) Outlook 2003 Report. Boston: Tufts CSDD.
51. United Nations (UN) (2001) HIV/AIDS: a Call To Action. Paper presented at the African Summit On HIV/AIDS, Tuberculosis and Other Related Communicable Diseases, 24-27 April, Abuja, Nigeria.
52. United Nations Development Programme (UNDP) (2001) Human Development Report 2001. Making New Technologies Work for Human Development. New York: Oxford Univ. Press.
53. United Nations Development Programme (UNDP) (2003) Human Development Report 2003. Millennium Development Goals: A Compact Among Nations to end Human Poverty. New York: Oxford Univ. Press.
54. World Bank (2003) World Development Report, Sustainable Development in a Dynamic World: Transforming Institutions, Growth, and Quality of Life. New York: Oxford Univ. Press.
55. World Health Organization (WHO) (2003) The World Health Report 2003. Geneva: WHO.
56. World Health Organization (WHO) and UNAIDS (1999) Report of the Overview of Vaccine Research in WHO and UNAIDS. Geneva: WHO.
57. World Health Organization (WHO). Commission On Macroeconomics and Health (2001) Investing for Economics Development. Geneva: WHO.
58. World Health Organization (WHO) and United Nations Children's Fund (UNICEF) (1996) The State of the World's Vaccines and Immunization. Geneva: WHO.
59. World Health Organization (WHO) and United Nations Children's Fund (UNICEF) (2002) State Of The World's Vaccine and Immunisation. Geneva: WHO.